dewmoore
Nov 21, 8:10 PM
We just had AWESOME news with
$SLS—sitting at
$2.8B–
$2.9B market cap after Phase 3 REGAL and closing a
$172.5M raise.
I wanted
$JNJ or
$LLY … but honestly, it’s starting to sound like
$MRK might be our new daddy 👀
Merck paid
$6.7B for Terns back in March (which was only in Phase 1/2) to build out blood cancers.
Then on Nov 17—the VERY SAME DAY
$SLS dropped its Phase 3 REGAL news—
$MRK pulled the plug on its Phase 3 blood-cancer drug because it was FAILING leaving a HUGE blood-cancer hole right when
$SLS delivered.
Look at the rest of the dots people are connecting:
• Just like Terns months ahead of its deal,
$SLS amended exec terms in June (lump-sum change-of-control shifts) + entered a quiet period
• Just like Terns,
$SLS raised millions (
$172.5M closed) BEFORE any buyout—giving it cash leverage for FDA/BLA prep or Q1 pipeline moves!
• Years of GPS + Keytruda history
Hard not to wonder if Merck is looking our way. J&J and Lilly can watch from the sidelines 👀
1 replies